Form 13-F position report

ALX ONCOLOGY HLDGS INC

Reported by Vivo Capital LLC

Company profile Manager portfolio Source filing
ALXO CUSIP 00166B105 Manager CIK 0001674712
Latest reported change

Reported 4,220,048 shares, unchanged from the prior quarter.

Reported value 17.8%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 5.48% This manager · Q4 2022
Shares 4,220,048 Quarter-end amount reported
Reported value $47,560,000 Fair value at quarter end
Consecutive quarters held 10 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Unchanged 3,184,713 0 (0.0%) 0.6% $6,592,356 2026-08-14
Q1 2026 New 3,184,713 +3,184,713 (0.0%) 0.53% $6,385,350 2026-05-15
Q4 2024 Reduced 0 -4,034,522 (-100.0%) 0 $0 2025-02-13
Q3 2024 Reduced 4,034,522 -185,526 (-4.4%) 0.61% $7,342,830 2024-11-13
Q2 2024 Unchanged 4,220,048 0 (0.0%) 2.35% $25,446,889 2024-08-14
Q1 2024 Unchanged 4,220,048 0 (0.0%) 3.7% $47,053,535 2024-04-22
Q4 2023 Unchanged 4,220,048 0 (0.0%) 5.14% $62,836,515 2024-02-07
Q3 2023 Unchanged 4,220,048 0 (0.0%) 2.22% $20,256,230 2023-11-08
Q2 2023 Unchanged 4,220,048 0 (0.0%) 2.19% $31,692,560 2023-08-14
Q1 2023 Unchanged 4,220,048 0 (0.0%) 1.32% $19,074,617 2023-05-15
Q4 2022 Unchanged 4,220,048 0 (0.0%) 5.48% $47,560,000 2023-02-13
Q3 2022 Unchanged 4,220,048 0 (0.0%) 4.46% $40,386,000 2022-11-14
Q2 2022 Unchanged 4,220,048 0 (0.0%) 3.43% $34,140,000 2022-08-15
Q1 2022 Unchanged 4,220,048 0 (0.0%) 4.91% $71,319,000 2022-05-13
Q4 2021 Unchanged 4,220,048 0 (0.0%) 5.47% $90,689,000 2022-02-11
Q3 2021 Unchanged 4,220,048 0 (0.0%) 14.0% $311,693,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

105 managers reported ALX ONCOLOGY HLDGS INC for Q4 2022.

Manager Activity Shares Change % of reported 13F Reported value Tenure
venBio Partners LLC Unchanged 9,699,925 0 33.89% $109,318,155 10 qtrs
FMR LLC Added 6,113,428 +1,482,854 < 0.01% $68,898,334 10 qtrs
Vivo Capital LLC This report Unchanged 4,220,048 0 5.48% $47,560,000 10 qtrs
ORBIMED ADVISORS LLC Unchanged 2,871,000 0 0.63% $32,356,170 9 qtrs
Logos Global Management LP Reduced 2,349,600 -621,752 3.1% $26,479,992 10 qtrs
BlackRock Inc Added 1,701,086 +30,684 < 0.01% $19,171,240 10 qtrs
VANGUARD GROUP INC Added 1,425,298 +14,289 < 0.01% $16,063,109 10 qtrs
EVENTIDE ASSET MANAGEMENT LLC Unchanged 902,000 0 0.2% $10,165,540 2 qtrs
Cormorant Asset Management LP Reduced 612,079 -100,000 0.46% $6,898,000 10 qtrs
Redmile Group LLC Reduced 607,470 -144,627 0.28% $6,846,187 10 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 13, 2023
Filing type
13F-HR
Position type
Common

Voting authority reported

Sole
4,220,048
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.